| GALAPAGOS N.V. |
| Belgien |
| Gesundheit |
| BE0003818359 / A0EAT9 |
| GXE (Frankfurt) |
| FRA:GXE, ETR:GXE, GXE:GR |
| AEX |
| https://www.glpg.com/ |
|
Galapagos NV is a fully integrated biotechnology company headquartered in Mechelen, Belgium, dedicated to transforming patient outcomes through life-changing science and innovation in immunology and o..
>Volltext.. |
| 1825.76 Mio. EUR |
| -1168.21 Mio. EUR |
| 1128.87 Mio. EUR |
| - |
| 325.68 Mio. EUR |
| 4.94 EUR |
| 7.02 Mio. EUR |
| 89.18 Mio. EUR |
| -199.95 Mio. EUR |
| 19.61 |
| 303.5% |
| 333.15% |
| - |
| - |
| - |
| - |
| GALAPAGOS |
| 24.03.26 |
|
||||
|